---
document_datetime: 2025-12-02 05:44:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xaluprine.html
document_name: xaluprine.html
version: success
processing_time: 0.1384854
conversion_datetime: 2025-12-24 01:32:00.64181
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xaluprine (previously Mercaptopurine Nova Laboratories)

[RSS](/en/individual-human-medicine.xml/66608)

##### Authorised

This medicine is authorised for use in the European Union

mercaptopurine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Xaluprine](#more-information-on-xaluprine-736)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79596)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine.

Expand section

Collapse section

## What is Xaluprine?

Xaluprine is a medicine that contains the active substance mercaptopurine. It is available as an oral suspension.

## What is Xaluprine used for?

Xaluprine is used to treat children, adolescents and adults who have acute lymphoblastic leukaemia (ALL), a cancer of the lymphocytes (a type of white blood cell).

Because the number of patients with ALL is low, the disease is considered 'rare', and Xaluprine was designated an 'orphan medicine' (a medicine used in rare diseases) on 30 April 2009.

The medicine can only be obtained with a prescription.

## How is Xaluprine used?

Treatment with this medicine should be supervised by a healthcare professional experienced in treating patients with ALL.

The medicine is taken by mouth, using the syringe provided in the pack, once per day in the evening. The dose is determined for each patient mainly by body surface area and may be adjusted according to its effects in the blood. It can be taken with food (except dairy products) or on an empty stomach but this should be consistent from day to day. For more information, see the summary of product characteristics (also part of the EPAR).

## How does Xaluprine work?

The active substance in this medicine, mercaptopurine has a similar chemical structure to purine, which is one of the fundamental chemicals that make up DNA. In the body, 6-mercaptopurine is converted within cells into a substance that interferes with the production of new DNA. This prevents the cells from dividing. In ALL, the lymphocytes multiply too quickly and live for too long. 6-Mercaptopurine prevents them from dividing and they eventually die, thereby slowing down the progression of the leukaemia. Medicines containing mercaptopurine in tablet form have been already used in the European Union (EU) for many years to treat patients with ALL.

## How has Xaluprine been studied?

Because 6-mercaptopurine has been used for the treatment of ALL in the EU for a number of years in tablet form, the company presented results from the scientific literature of studies previously carried out with mercaptopurine tablets.

A study was also carried out to compare the bioavailability of Xaluprine, which is an oral suspension, with that of the tablet. The bioavailability study compared the way the two different forms of the same medicine are absorbed in the human body and the levels of the active substance they produce.

## What benefit has Xaluprine shown during the studies?

The effectiveness of 6-mercaptopurine in slowing down the progression of ALL is already well known since it has been used for many years. The added benefit of Xaluprine is that, as an oral suspension, it will provide more accuracy in dosing and it is easier to be taken by children. The bioavailability study showed that Xaluprine is comparable to the tablets, but it works in a more predictable way and has a higher rate of absorption, for which reason the dose will need to be adjusted when a patient switches from one formulation to the other.

## What is the risk associated with Xaluprine?

The most common side effects with mercaptopurine (seen in more than 1 patient in 10) are leucopenia (low white blood cell counts) and thrombocytopenia (low blood platelet counts). For the full list of all side effects, see the package leaflet.

Xaluprine must not be used in people who are hypersensitive (allergic) to mercaptopurine or any of the other ingredients. It must also not be used at the same time as patients are having a yellow fever vaccination.

## Why has Xaluprine been approved?

The CHMP noted that mercaptopurine is established as an important treatment for ALL and that the only authorised form in the EU is a 50-mg tablet, making it difficult to adjust the dose for smaller children. The Committee considered that an oral suspension allows more accurate dosing and is more convenient for children unable to swallow tablets. The CHMP also noted that the risks of using the medicine are well known.

The Committee concluded that the benefits of Xaluprine are greater than its risks and recommended that it be granted marketing authorisation.

## Other information about Xaluprine

The European Commission granted a marketing authorisation valid throughout the European Union for Xaluprine on 9 March 2012.

For more information about treatment with Xaluprine, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Xaluprine : EPAR - Summary for the public

Adopted

Reference Number: EMA/648641/2011

English (EN) (56.83 KB - PDF)

**First published:** 28/03/2012

**Last updated:** 27/09/2012

[View](/en/documents/overview/xaluprine-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-919)

български (BG) (95.82 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/bg/documents/overview/xaluprine-epar-summary-public_bg.pdf)

español (ES) (57.63 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/es/documents/overview/xaluprine-epar-summary-public_es.pdf)

čeština (CS) (86.6 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/cs/documents/overview/xaluprine-epar-summary-public_cs.pdf)

dansk (DA) (57.58 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/da/documents/overview/xaluprine-epar-summary-public_da.pdf)

Deutsch (DE) (118.04 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/de/documents/overview/xaluprine-epar-summary-public_de.pdf)

eesti keel (ET) (117.04 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/et/documents/overview/xaluprine-epar-summary-public_et.pdf)

ελληνικά (EL) (158.53 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/el/documents/overview/xaluprine-epar-summary-public_el.pdf)

français (FR) (117.49 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/fr/documents/overview/xaluprine-epar-summary-public_fr.pdf)

italiano (IT) (119.83 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/it/documents/overview/xaluprine-epar-summary-public_it.pdf)

latviešu valoda (LV) (99.01 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/lv/documents/overview/xaluprine-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (84.33 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/lt/documents/overview/xaluprine-epar-summary-public_lt.pdf)

magyar (HU) (140.26 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/hu/documents/overview/xaluprine-epar-summary-public_hu.pdf)

Malti (MT) (145.19 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/mt/documents/overview/xaluprine-epar-summary-public_mt.pdf)

Nederlands (NL) (133.43 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/nl/documents/overview/xaluprine-epar-summary-public_nl.pdf)

polski (PL) (145.41 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/pl/documents/overview/xaluprine-epar-summary-public_pl.pdf)

português (PT) (56.82 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/pt/documents/overview/xaluprine-epar-summary-public_pt.pdf)

română (RO) (142.13 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/ro/documents/overview/xaluprine-epar-summary-public_ro.pdf)

slovenčina (SK) (142.98 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/sk/documents/overview/xaluprine-epar-summary-public_sk.pdf)

slovenščina (SL) (80.73 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/sl/documents/overview/xaluprine-epar-summary-public_sl.pdf)

Suomi (FI) (116.8 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/fi/documents/overview/xaluprine-epar-summary-public_fi.pdf)

svenska (SV) (72.29 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

27/09/2012

[View](/sv/documents/overview/xaluprine-epar-summary-public_sv.pdf)

## Product information

Xaluprine : EPAR - Product Information

Adopted

English (EN) (279.94 KB - PDF)

**First published:** 24/06/2024

**Last updated:** 25/09/2025

[View](/en/documents/product-information/xaluprine-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-848)

български (BG) (420.66 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/bg/documents/product-information/xaluprine-epar-product-information_bg.pdf)

español (ES) (292.42 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/es/documents/product-information/xaluprine-epar-product-information_es.pdf)

čeština (CS) (393.83 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/cs/documents/product-information/xaluprine-epar-product-information_cs.pdf)

dansk (DA) (285.05 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/da/documents/product-information/xaluprine-epar-product-information_da.pdf)

Deutsch (DE) (306.79 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/de/documents/product-information/xaluprine-epar-product-information_de.pdf)

eesti keel (ET) (277.71 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/et/documents/product-information/xaluprine-epar-product-information_et.pdf)

ελληνικά (EL) (432.78 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/el/documents/product-information/xaluprine-epar-product-information_el.pdf)

français (FR) (305.44 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/fr/documents/product-information/xaluprine-epar-product-information_fr.pdf)

hrvatski (HR) (398.33 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/hr/documents/product-information/xaluprine-epar-product-information_hr.pdf)

íslenska (IS) (826.6 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/is/documents/product-information/xaluprine-epar-product-information_is.pdf)

italiano (IT) (843.16 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/it/documents/product-information/xaluprine-epar-product-information_it.pdf)

latviešu valoda (LV) (930.96 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/lv/documents/product-information/xaluprine-epar-product-information_lv.pdf)

lietuvių kalba (LT) (894.76 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/lt/documents/product-information/xaluprine-epar-product-information_lt.pdf)

magyar (HU) (408.78 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/hu/documents/product-information/xaluprine-epar-product-information_hu.pdf)

Malti (MT) (867.68 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/mt/documents/product-information/xaluprine-epar-product-information_mt.pdf)

Nederlands (NL) (841.53 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/nl/documents/product-information/xaluprine-epar-product-information_nl.pdf)

norsk (NO) (855.44 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/no/documents/product-information/xaluprine-epar-product-information_no.pdf)

polski (PL) (942.78 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/pl/documents/product-information/xaluprine-epar-product-information_pl.pdf)

português (PT) (824.93 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/pt/documents/product-information/xaluprine-epar-product-information_pt.pdf)

română (RO) (926.04 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/ro/documents/product-information/xaluprine-epar-product-information_ro.pdf)

slovenčina (SK) (920.09 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/sk/documents/product-information/xaluprine-epar-product-information_sk.pdf)

slovenščina (SL) (896.39 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/sl/documents/product-information/xaluprine-epar-product-information_sl.pdf)

Suomi (FI) (287.75 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/fi/documents/product-information/xaluprine-epar-product-information_fi.pdf)

svenska (SV) (883.51 KB - PDF)

**First published:**

24/06/2024

**Last updated:**

25/09/2025

[View](/sv/documents/product-information/xaluprine-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000300720 24/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xaluprine : EPAR - All Authorised presentations

English (EN) (61 KB - PDF)

**First published:** 28/03/2012

**Last updated:** 25/05/2023

[View](/en/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-67)

български (BG) (39.58 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/bg/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.32 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/es/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.65 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/cs/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.49 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/da/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.96 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/de/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (36.09 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/et/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.57 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/el/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_el.pdf)

français (FR) (36.64 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/fr/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (104.13 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/hr/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (37.1 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/is/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36.43 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/it/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (40.17 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/lv/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.74 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/lt/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (37.99 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/hu/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (41.02 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/mt/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.53 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/nl/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.06 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/no/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_no.pdf)

polski (PL) (40.7 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/pl/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.07 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/pt/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.55 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/ro/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (45.55 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/sk/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.45 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/sl/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (35.35 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/fi/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (36.49 KB - PDF)

**First published:**

28/03/2012

**Last updated:**

25/05/2023

[View](/sv/documents/all-authorised-presentations/xaluprine-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xaluprine (previously Mercaptopurine Nova Laboratories) Active substance 6-mercaptopurine monohydrate International non-proprietary name (INN) or common name mercaptopurine Therapeutic area (MeSH) Leukemia, Lymphoid Anatomical therapeutic chemical (ATC) code L01BB02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

## Authorisation details

EMA product number EMEA/H/C/002022 Marketing authorisation holder

Lipomed GmbH

Hegenheimer Strasse 2

Opinion adopted 21/07/2011 Marketing authorisation issued 09/03/2012 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xaluprine : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (346.56 KB - PDF)

**First published:** 20/08/2025

**Last updated:** 25/09/2025

[View](/en/documents/procedural-steps-after/xaluprine-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xaluprine : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (211.31 KB - PDF)

**First published:** 27/09/2012

**Last updated:** 20/08/2025

[View](/en/documents/procedural-steps-after/xaluprine-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xaluprine-H-C-PSUSA-00001988-202309 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/294389/2024

English (EN) (135.68 KB - PDF)

**First published:** 24/06/2024

[View](/en/documents/scientific-conclusion/xaluprine-h-c-psusa-00001988-202309-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Xaluprine-H-C-PSUSA-00001988-202109 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/943492/2022

English (EN) (117.05 KB - PDF)

**First published:** 15/12/2022

[View](/en/documents/scientific-conclusion/xaluprine-h-c-psusa-00001988-202109-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xaluprine-H-C-PSUSA-00001988-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/480962/2017

English (EN) (70.46 KB - PDF)

**First published:** 28/07/2017

**Last updated:** 28/07/2017

[View](/en/documents/scientific-conclusion/xaluprine-h-c-psusa-00001988-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xaluprine-H-C-2022-PSUV-08 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/749978/2014

English (EN) (67.49 KB - PDF)

**First published:** 09/12/2014

**Last updated:** 09/12/2014

[View](/en/documents/scientific-conclusion/xaluprine-h-c-2022-psuv-08-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xaluprine-H-C-2022-PSUV-0006 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/39286/2014

English (EN) (67.75 KB - PDF)

**First published:** 06/02/2014

**Last updated:** 06/02/2014

[View](/en/documents/scientific-conclusion/xaluprine-h-c-2022-psuv-0006-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Mercaptopurine Nova Laboratories : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/668488/2011

English (EN) (471.4 KB - PDF)

**First published:** 28/03/2012

**Last updated:** 28/03/2012

[View](/en/documents/assessment-report/mercaptopurine-nova-laboratories-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mercaptopurine Nova Laboratories

Adopted

Reference Number: EMA/CHMP/470877/2011

English (EN) (62.94 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 22/07/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mercaptopurine-nova-laboratories_en.pdf)

#### More information on Xaluprine

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-09-628) on 30 April 2009. Xaluprine was withdrawn from the Community register of orphan medicinal products in March 2022 at the end of the 10-year period of market exclusivity.

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Xaluprine : EPAR - Product information - tracked changes

English (EN) (258.68 KB - DOCX)

**First published:** 25/09/2025

[View](/en/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-919)

български (BG) (241.12 KB - DOCX)

**First published:**

25/09/2025

[View](/bg/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_bg.docx)

español (ES) (260.12 KB - DOCX)

**First published:**

25/09/2025

[View](/es/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_es.docx)

čeština (CS) (271.29 KB - DOCX)

**First published:**

25/09/2025

[View](/cs/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (261.2 KB - DOCX)

**First published:**

25/09/2025

[View](/da/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (270.88 KB - DOCX)

**First published:**

25/09/2025

[View](/de/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (254.26 KB - DOCX)

**First published:**

25/09/2025

[View](/et/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (276.42 KB - DOCX)

**First published:**

25/09/2025

[View](/el/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_el.docx)

français (FR) (279.7 KB - DOCX)

**First published:**

25/09/2025

[View](/fr/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (274.7 KB - DOCX)

**First published:**

25/09/2025

[View](/hr/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (259.92 KB - DOCX)

**First published:**

25/09/2025

[View](/is/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_is.docx)

italiano (IT) (264.4 KB - DOCX)

**First published:**

25/09/2025

[View](/it/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (268.96 KB - DOCX)

**First published:**

25/09/2025

[View](/lv/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (264.78 KB - DOCX)

**First published:**

25/09/2025

[View](/lt/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (264.67 KB - DOCX)

**First published:**

25/09/2025

[View](/hu/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (194.16 KB - DOCX)

**First published:**

25/09/2025

[View](/mt/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (267.96 KB - DOCX)

**First published:**

25/09/2025

[View](/nl/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (259.28 KB - DOCX)

**First published:**

25/09/2025

[View](/no/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_no.docx)

polski (PL) (272.7 KB - DOCX)

**First published:**

25/09/2025

[View](/pl/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_pl.docx)

português (PT) (263.58 KB - DOCX)

**First published:**

25/09/2025

[View](/pt/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_pt.docx)

română (RO) (270.16 KB - DOCX)

**First published:**

25/09/2025

[View](/ro/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (277.09 KB - DOCX)

**First published:**

25/09/2025

[View](/sk/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (256.68 KB - DOCX)

**First published:**

25/09/2025

[View](/sl/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (258.66 KB - DOCX)

**First published:**

25/09/2025

[View](/fi/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (257.12 KB - DOCX)

**First published:**

25/09/2025

[View](/sv/documents/product-information-tracked-changes/xaluprine-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/09/2025

## Share this page

[Back to top](#main-content)